Skip to main content
Premium Trial:

Request an Annual Quote

Almac to Partner with Lilly UK on Lung Cancer Dx

NEW YORK (GenomeWeb News) – Almac Diagnostics said today that it will collaborate with Lilly UK to develop a companion diagnostic for a combination lung cancer therapy.

The companies will evaluate a predictive marker for a drug combination used in treating non-squamous, non-small cell lung cancer patients. Specifically, they will study Thymidylate Synthase as a marker for response to the Eli Lilly drug pemetrexid (Alimta) in combination with cisplatin.

They also will study "alternative strategies" for developing other markers for the same combination therapy. The alternative studies will involve using global gene expression profiling from formalin-fixed paraffin-embedded tumor samples using Almac's Lung Cancer DSA microarray.

Almac said it will conduct global gene expression profiling, microRNA profiling, SNP genotyping, qPCR validation, and data analysis to develop the companion diagnostic.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.